Department of Pathology, Oslo University Hospital, Norway; Center for Laboratory Medicine, Østfold Hospital Trust, Norway.
Norwegian Cervical Cancer Screening Programme, Cancer Registry of Norway, Oslo, Norway.
Gynecol Oncol. 2018 Jan;148(1):111-117. doi: 10.1016/j.ygyno.2017.10.031. Epub 2017 Nov 11.
To explore the HPVgenotype profile in Norwegian women with ASC-US/LSIL cytology and the subsequent risk of high-grade cervical neoplasia (CIN 3+).
In this observational study delayed triage of ASC-US/LSIL of 6058 women were included from 2005 to 2010. High-risk HPV detection with Hybrid Capture 2 (HC2) was used and the HC2+ cases were genotyped with in-house nmPCR. Women were followed-up for histologically confirmed CIN3+ within three years of index HPV test by linkage to the screening databases at the Cancer Registry of Norway.
HC2 was positive in 45% (2756/6058) of the women. Within 3years CIN3+ was diagnosed in 26% of women<34year and in 15%≥34year. HC2 was positive at index in 94% of CIN3+ cases and negative in 64 cases including three women with cervical carcinomas. Women<34years with single infections of HPV 16, 35, 58 or 33 or multiple infections including HPV 16, 52, 33 or 31 were associated with highest proportions of CIN 3+. Older women with single infection with HPV 16, 33, 31 or 35 or multiple infections including HPV 16, 33, 31 or 18/39 were more likely to develop CIN 3+.
HPV 16 and HPV 33 at baseline both as single or multiple infections, were associated with the highest risk for CIN3+. Among older women, all 13 high-risk genotypes as single infection were associated with >20% risk of CIN3+. Further studies are necessary to risk stratify the individual genotypes to reduce the number of colposcopies in Norway.
探讨挪威 ASC-US/LSIL 细胞学患者的 HPV 基因型谱及其随后发生高级别宫颈癌(CIN3+)的风险。
在这项观察性研究中,纳入了 2005 年至 2010 年间 6058 例 ASC-US/LSIL 延迟分类的女性。采用杂交捕获 2(HC2)检测高危型 HPV,对 HC2+病例采用内部 nmPCR 进行基因分型。通过与挪威癌症登记处的筛查数据库进行链接,对索引 HPV 检测后三年内组织学确诊为 CIN3+的女性进行随访。
6058 例女性中,HC2 阳性率为 45%(2756/6058)。3 年内,<34 岁的女性中有 26%诊断为 CIN3+,≥34 岁的女性中有 15%诊断为 CIN3+。94%的 CIN3+病例在索引时 HC2 阳性,而在 64 例阴性病例中包括 3 例宫颈癌患者。<34 岁的女性中,HPV 16、35、58 或 33 单一感染或 HPV 16、52、33 或 31 多重感染与 CIN3+比例最高相关。年龄较大的女性中,HPV 16、33、31 或 35 单一感染或 HPV 16、33、31 或 18/39 多重感染与发生 CIN3+的可能性更大。
基线时 HPV 16 和 HPV 33 单一或多重感染均与 CIN3+风险最高相关。在年龄较大的女性中,所有 13 种高危基因型单一感染均与 CIN3+风险>20%相关。需要进一步研究以对个体基因型进行风险分层,从而减少挪威的阴道镜检查数量。